Literature DB >> 22936320

Effect of Yisui Shengxue Granule () on the oxidative damage of erythrocytes from patients with hemoglobin H disease.

Wen-Juan Wang1, Zhi-Kui Wu, Xin-Hua Zhang, Yong-Mei Liu, Su-Ping Fang, Chong Zhang, Wen-Jun Liu, Min Li, Rong-Xin Wang, Rui-Gui Luo, Ping-Ping Li.   

Abstract

OBJECTIVE: To investigate the effect of Yisui Shengxue Granule (, YSSXG), a complex Chinese medicine, on the oxidative damage of erythrocytes from patients with hemoglobin H (HbH) disease.
METHODS: Twenty-two patients with HbH disease and 22 healthy volunteers were observed. YSSXG was given to patients with HbH disease for 3 months. Before and after the 3-month treatment, blood parameters [hemoglobin (Hb), red blood cells (RBCs), and reticulocyte percent (Ret)] were examined; inclusion bodies in erythrocytes were observed by transmission electron microscopy (TEM); activities of antioxidant defense enzymes [superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (Cat)] and erythrocyte membrane malondialdehyde (MDA) concentrations were determined.
RESULTS: In patients with HbH disease, measured values of RBC and Hb obtained from the first to the third months after treatment with YSSXG were significantly higher than before treatment (P<0.01). Measured values of Ret from the second to the third months after treatment were significantly lower than before treatment (P<0.05 and P<0.01, respectively). Prior to treatment with YSSXG, TEM images of RBCs showed the presence of numerous inclusion bodies. After treatment with YSSXG, the amount and volume of inclusion bodies decreased. Treatment with YSSXG also led to a significant increase in SOD activity (P<0.01), a decrease in Cat activity (P<0.01), and no significant differences in GSHPx activity (P>0.05) or MDA concentration (P>0.05). However, compared with the healthy counterparts, SOD, GSH-Px, and Cat activities presented at high levels (P<0.01) both before and after treatment.
CONCLUSIONS: YSSXG could improve the degree of hemolysis and anemia in patients with HbH disease. The mechanism may be related to its antioxidative effects, which could elevate the activity of total SOD in erythrocytes and efficiently inhibit the oxidative precipitation of β-globin chains.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22936320     DOI: 10.1007/s11655-012-1202-z

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  21 in total

1.  Enhancement of erythrocyte superoxide dismutase activity: effects on cellular oxidant defense.

Authors:  M D Scott; J W Eaton; F A Kuypers; D T Chiu; B H Lubin
Journal:  Blood       Date:  1989-11-15       Impact factor: 22.113

2.  The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes.

Authors:  J T DODGE; C MITCHELL; D J HANAHAN
Journal:  Arch Biochem Biophys       Date:  1963-01       Impact factor: 4.013

3.  The unusual pathobiology of hemoglobin constant spring red blood cells.

Authors:  S L Schrier; A Bunyaratvej; A Khuhapinant; S Fucharoen; M Aljurf; L M Snyder; C R Keifer; L Ma; N Mohandas
Journal:  Blood       Date:  1997-03-01       Impact factor: 22.113

4.  Hematologic improvement following splenectomy for hemoglobin-H disease.

Authors:  G M Wagner; S A Liebhaber; H O Cutting; S H Embury
Journal:  West J Med       Date:  1982-10

5.  Genetic and clinical features of hemoglobin H disease in Chinese patients.

Authors:  F E Chen; C Ooi; S Y Ha; B M Cheung; D Todd; R Liang; T K Chan; V Chan
Journal:  N Engl J Med       Date:  2000-08-24       Impact factor: 91.245

6.  The fate of excess beta-globin chains within erythropoietic cells in alpha-thalassaemia 2 trait, alpha-thalassaemia 1 trait, haemoglobin H disease and haemoglobin Q-H disease: an electron microscope study.

Authors:  S N Wickramasinghe; M Hughes; S Fucharoen; P Wasi
Journal:  Br J Haematol       Date:  1984-03       Impact factor: 6.998

7.  Comparison of erythrocyte antioxidative enzyme activities between two types of haemoglobin H disease.

Authors:  S Prasartkaew; A Bunyaratvej; S Fucharoen; P Wasi
Journal:  J Clin Pathol       Date:  1986-12       Impact factor: 3.411

8.  [Clinical observation of Yisui Shengxue Granule in treating 25 patients with hemoglobin H disease].

Authors:  Wen-Juan Wang; Zhi-Kui Wu; Xin-Hua Zhang; Yong-Mei Liu; Su-Ping Fang; Rong-Xin Wang; Chong Zhang; Ping-Ping Li; Rui-Gui Luo
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2008-02

Review 9.  Free radical metabolism in human erythrocytes.

Authors:  M Y Burak Cimen
Journal:  Clin Chim Acta       Date:  2008-01-18       Impact factor: 3.786

10.  Erythrocyte superoxide dismutase, catalase activities and plasma nitrite and nitrate levels in patients with Behçet disease and recurrent aphthous stomatitis.

Authors:  K Gunduz; G Ozturk; E Y Sozmen
Journal:  Clin Exp Dermatol       Date:  2004-03       Impact factor: 3.470

View more
  3 in total

1.  Effect of Chinese Herbal Medicine Therapy on Risks of Overall, Diabetes-Related, and Cardiovascular Diseases-Related Mortalities in Taiwanese Patients With Hereditary Hemolytic Anemias.

Authors:  Mu-Lin Chiu; Jian-Shiun Chiou; Chao-Jung Chen; Wen-Miin Liang; Fuu-Jen Tsai; Yang-Chang Wu; Ting-Hsu Lin; Chiu-Chu Liao; Shao-Mei Huang; Chen-Hsing Chou; Cheng-Wen Lin; Te-Mao Li; Yu-Lung Hsu; Ying-Ju Lin
Journal:  Front Pharmacol       Date:  2022-05-30       Impact factor: 5.988

2.  Molecular mechanism of yisui shengxue granule, a complex chinese medicine, on thalassemia patients suffering from hemolysis and anemia of erythrocytes.

Authors:  Na-Li Chu; Zhi-Kui Wu; Xin-Hua Zhang; Su-Ping Fang; Wen-Juan Wang; Yan-Ling Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2014-12-10       Impact factor: 2.629

3.  Clinical Effect and Mechanism of Yisui Shengxue Granules in Thalassemia Patients with Mild, Moderate, or Severe Anemia.

Authors:  Yan-Ling Cheng; Xin-Hua Zhang; Yu-Wen Sun; Wen-Juan Wang; Su-Ping Fang; Zhi-Kui Wu
Journal:  Evid Based Complement Alternat Med       Date:  2016-02-02       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.